Alivus Life Sciences Limited
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
What Alivus files
- Investor Meet54
- Others29
- Updates18
- Important9
- Board Meeting8
- PPTs7
Alivus Life Sciences' board approved acquiring a 76% stake in IQGEN-X Pharma for ~₹9.12 Cr cash. This expands Alivus's offerings in the API & CDMO space, providing end-to-end solutions. IQGEN-X specializes in pharmaceutical formulation development and reported FY26 turnover of ₹3.48 Cr.
Alivus Life Sciences announced its Q1 financial results: Revenue from operations hit ₹640.41 Cr, with net profit at ₹160.08 Cr. Basic EPS for the quarter was ₹13.04. #AlivusLifeSciences #Q1Results
Alivus Life Sciences' board has approved audited financial results for Q4 & FY26, reporting revenue of ₹2,551.83 Cr and profit of ₹564.48 Cr. They also proposed a final dividend of ₹5 per share, pending shareholder approval.
Alivus Life Sciences reports Q3 financial results: Revenue from operations hit ₹672.89 Cr, with a profit of ₹150.26 Cr. For the nine months ending Dec 31, 2025, revenue reached ₹1862.72 Cr and profit stood at ₹401.82 Cr.
Alivus Life Sciences' board approved the financial results for the quarter and half-year ended Sept 30. Q2 revenue surged to ₹587.98 Cr & net profit to ₹130.03 Cr. H1 revenue hit ₹1189.83 Cr, with net profit at ₹251.56 Cr, showing solid growth.